

Dr. Reddy's revenues cross \$2 billion milestone

April 24, 2012 | Company results | By BioSpectrum Bureau

Dr. Reddy's cross \$2 billion mark



Hyderabad: Dr. Reddy's Laboratories announced its audited consolidated financial results for the quarter and full year ended March 31, 2012 under International Financial Reporting Standards (IFRS).

Consolidated revenues for the company stood at \$1788.3 million (Rs 96.7 billion) in FY12 showing year-on-year growth of 30 percent. The growth was primarily driven by key markets of North America and Russia in global generics segment and pharmaceutical services and active ingredients segment. The company noted the EBITDA of \$465.7 million (Rs 25.4 billion) in FY12 and the profit after tax in FY12 was \$279.4 million (Rs 15.3 billion) showing a YoY growth of 42 percent.

During the year, the company also launched 141 new generic products, filed 88 new product registrations and filed 68 DMFs globally.